Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab

Bernhard Scheiner,Riccardo Sartoris,Antonio D'Alessio,Claudia Fulgenzi,Katharina Pomej,Lorenz Balcar,Mohamed Bouattour,Sabrina Sidali,Vera Himmelsbach,Fabian Finkelmeier,Kornelius Schulze,Johann von Felden,Florian Hucke,Kateryna Shmanko,Alexander Siebenhuner,Joachim C. Mertens,Sara De Dosso,Matthias Ebert,Andreas Teufel,Dirk-Thomas Waldschmidt,Iuliana Pompilia Radu,Anja Krall,Michael Trauner,Jean-Francois Dufour,Henning Wege,Arndt Weinmann,Joerg Trojan,Rudolf E. Stauber,Markus Peck-Radosavljevic,Wei-Fan Hsu,Arndt Vogel,Maxime Ronot,David J. Pinato,Matthias Pinter

Journal of Hepatology（2023）

Cited 0|Views11
No score
Abstract
Background We recently developed the CRP and AFP in Immunotherapy (CRAFITY) score in patients with HCC undergoing immune checkpoint inhibitor (ICI) therapy. As CRAFITY was developed in patients undergoing different ICI-based regimens, the score requires validation in patients treated with atezolizumab and bevacizumab (AB).
More
Translated text
Key words
hepatocellular carcinoma,atezolizumab,bevacizumab,crafity score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined